<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01253694</url>
  </required_header>
  <id_info>
    <org_study_id>DME-NERA</org_study_id>
    <nct_id>NCT01253694</nct_id>
  </id_info>
  <brief_title>Ranibizumab as a Rescue Therapy for Diabetic Macular Edema</brief_title>
  <official_title>Ranibizumab in Residual Diabetic Macular Edema Following Previous Intravitreal Bevacizumab Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Retina Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New England Retina Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment with Ranibizumab of the residual diabetic edema in patients with failed response to&#xD;
      Bevacizumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with resolution of diabetic macular edema compared to baseline as determined by mean foveal thickness on Spectralis &lt; 300 microns.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the main change in BCVA (best corrected visual acuity) score over time</measure>
    <time_frame>6-12 months</time_frame>
    <description>They will evaluate the amount of patients gaining 3 or more letters and the amount of patients losing 3 or more letters.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Patients with 3-5 consecutive Avastin injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will receive 0.5 mg of intravitreal Ranibizumab monthly for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with 6 or more consecutive injections of Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 0.5 mg of intravitreal Ranibizumab during the first 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>injection of 0.5 mg of Intravitreal Ranibizumab</intervention_name>
    <description>Following the sterile technique, intravitreal injection of anti-VEGF is applied</description>
    <arm_group_label>Patients with 3-5 consecutive Avastin injections</arm_group_label>
    <arm_group_label>Patients with 6 or more consecutive injections of Bevacizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects will be eligible if the following criteria are met:&#xD;
&#xD;
          1. Age &gt; 18 years&#xD;
&#xD;
          2. Diagnosis of diabetes mellitus (type 1 or 2)&#xD;
&#xD;
          3. Residual edema as determined by mean foveal thickness on Spectralis OCT (optical&#xD;
             coherence tomography) &gt; 300 microns and leakage seen on FA at baseline&#xD;
&#xD;
          4. Clinical evidence of retinal thickening due to macular edema involving the center of&#xD;
             the macula, associated with diabetic retinopathy.&#xD;
&#xD;
          5. Previous history of at least 3-5 or more consecutive 1.25 mg of intravitreal&#xD;
             bevacizumab injections for the treatment of diabetic macular edema (consecutive&#xD;
             injections administered no more than 6 weeks apart).&#xD;
&#xD;
          6. BCVA of 20/32-20/400 using Early Treatment Diabetic Retinopathy Study (ETDRS)&#xD;
&#xD;
          7. Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT&#xD;
             testing and retinal photography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women&#xD;
             not using adequate contraception.&#xD;
&#xD;
          2. Participation in another ocular investigation or trial simultaneously.&#xD;
&#xD;
          3. Systemic use of anti-VEGF within 3 months prior to day 0.&#xD;
&#xD;
          4. Blood pressure &gt; 180/110 (systolic above 180 OR diastolic above 110)&#xD;
&#xD;
          5. Any condition that, in the opinion of the investigator, would preclude participation&#xD;
             in the study (e.g. chronic alcoholism, drug abuse).&#xD;
&#xD;
          6. Evidence of vitreoretinal interface abnormality after ocular exam or OCT that may be&#xD;
             contributing to the macular edema.&#xD;
&#xD;
          7. An eye that, in the investigator's opinion, has no chance of improving in visual&#xD;
             acuity following resolution of macular edema (e.g. presence of subretinal fibrosis,&#xD;
             ischemic maculopathy or geographic atrophy).&#xD;
&#xD;
          8. Presence of another ocular condition that may affect the visual acuity or macular&#xD;
             edema during the course of the study (e.g. Age-related Macular Degeneration, uveitis,&#xD;
             Irvine-Gass).&#xD;
&#xD;
          9. Evidence of active neovascularization of the iris or retina.&#xD;
&#xD;
         10. Evidence of central atrophy or fibrosis in the study eye.&#xD;
&#xD;
         11. Presence of substantial cataract, one that might decrease the vision by 3 or more&#xD;
             lines of vision at sometime during the study.&#xD;
&#xD;
         12. History of vitreous surgery in the study eye.&#xD;
&#xD;
         13. History of cataract surgery within 6 months of enrollment.&#xD;
&#xD;
         14. History of YAG capsulotomy within 2 months of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nauman Chaudhry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New England Retina Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New England Retina Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>November 30, 2010</study_first_submitted>
  <study_first_submitted_qc>December 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <last_update_submitted>May 1, 2013</last_update_submitted>
  <last_update_submitted_qc>May 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>edema</keyword>
  <keyword>ranibizumab</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

